614 related articles for article (PubMed ID: 31900109)
1. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
Fritzell S; Sandén E; Eberstål S; Visse E; Darabi A; Siesjö P
Cancer Immunol Immunother; 2013 Sep; 62(9):1463-74. PubMed ID: 23775421
[TBL] [Abstract][Full Text] [Related]
3. Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Lin CY; Li RJ; Huang CY; Wei KC; Chen PY
J Drug Target; 2018 Apr; 26(4):325-332. PubMed ID: 28911239
[TBL] [Abstract][Full Text] [Related]
4. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
5. Liposomal temozolomide drug delivery using convection enhanced delivery.
Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts.
Sugiyama S; Yamashita Y; Kikuchi T; Sonoda Y; Kumabe T; Tominaga T
Neurol Res; 2008 Nov; 30(9):960-7. PubMed ID: 18671903
[TBL] [Abstract][Full Text] [Related]
7. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
8. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
9. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
10. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
12. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
13. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Yokosawa M; Sonoda Y; Sugiyama S; Saito R; Yamashita Y; Nishihara M; Satoh T; Kumabe T; Yokoyama M; Tominaga T
Tohoku J Exp Med; 2010 Aug; 221(4):257-64. PubMed ID: 20622491
[TBL] [Abstract][Full Text] [Related]
14. Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
Zong Z; Hua L; Wang Z; Xu H; Ye C; Pan B; Zhao Z; Zhang L; Lu J; Mei LH; Rutong Y
Drug Deliv; 2019 Dec; 26(1):34-44. PubMed ID: 30744436
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Zhu X; Fujita M; Snyder LA; Okada H
J Neurooncol; 2011 Aug; 104(1):83-92. PubMed ID: 21116835
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Shi L; Li H; Gu J; Song C; Li J; Chen L; Zhou Q; Qi S; Lu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):69-74. PubMed ID: 33509755
[TBL] [Abstract][Full Text] [Related]
17. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
[TBL] [Abstract][Full Text] [Related]
19. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Kumari S; Ahsan SM; Kumar JM; Kondapi AK; Rao NM
Sci Rep; 2017 Jul; 7(1):6602. PubMed ID: 28747713
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Dai B; Qi N; Li J; Zhang G
Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]